IMMUNOPRECISE ANTIBODIES LTD - IPA STOCK NEWS

ImmunoPrecise Antibodies Ltd. (IPA) announced the identification of antibody 23-H7, which shows strong protective effects against SARS-CoV-2 in preclinical studies. This antibody disrupts the RBD-ACE2 interaction but is less susceptible to mutations than current therapies. In vivo studies indicated undetectable virus replication in most treated animals. IPA's PolyTope platform allows for combination therapies to enhance viral clearance, reducing the risk of escape mutations. This discovery underscores IPA's commitment to innovative antibody development and effective COVID-19 treatments.

ImmunoPrecise Antibodies reported a strong financial performance for Q3 of its fiscal 2021, with revenues rising 32% to $13,035,522 for the nine months ending January 31, 2021. The company achieved adjusted EBITDA of $2,564,257, a significant jump from $18,356 in the same period last year. A successful USD$21.7 million share offering was completed, enhancing their cash position to $15,720,057. The firm continues to advance its antibody discovery technology, forming partnerships with Genmab and Litevax to bolster shareholder value.

ImmunoPrecise Antibodies Ltd. (IPA) has announced the results of a PolyTope™ antibody interaction analysis against SARS-CoV-2 variants. A total of 27 proprietary antibodies were analyzed, demonstrating the ability to bind to multiple variants, including U.K., South African, and Brazilian strains. This positions IPA's antibody cocktails as a promising solution against mutational escape of the virus. The company's PolyTope platform aims to enhance treatment efficacy and reduce dosage requirements. CEO Jennifer Bath highlighted the need for multi-antibody therapies as single therapies do not provide long-term protection against evolving variants.

ImmunoPrecise Antibodies Ltd. (IPA) announced its participation in the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. CEO Jennifer Bath will provide a business overview and engage in one-on-one investor meetings. The company aims to showcase its innovative SARS-CoV-2 PolyTope monoclonal therapies designed to combat virus mutations effectively. This virtual conference presents a platform for institutional investors to connect with IPA, emphasizing the company’s commitment to leading therapeutic antibody development.

ImmunoPrecise Antibodies Ltd. (IPA) has reported promising preliminary preclinical results for its TATX-03 PolyTope antibody cocktail against SARS-CoV-2. In a hamster model, 100% of infected animals showed complete virus clearance from lungs and throats by day four post-treatment. The cocktail demonstrated efficacy in both therapeutic and prophylactic settings, significantly reducing viral load. This innovative approach targets multiple epitopes to minimize mutational escape risk. IPA plans final IND-enabling studies in late Q2 2021, aiming for clinical evaluation to further assess TATX-03's potential against COVID-19.

ImmunoPrecise Antibodies Ltd. (IPA) announced the full exercise of the over-allotment option related to its bought deal offering, resulting in the sale of 242,443 additional shares at $13.45 each, generating approximately $3.3 million in gross proceeds. These funds will be allocated towards expanding operations into certified practices, advancing therapeutic discovery programs, enhancing data analysis capabilities, and developing innovative COVID-19 therapeutics. The offering was exclusively conducted in the U.S., with the necessary regulatory filings made in Canada and with the SEC.

ImmunoPrecise Antibodies Ltd. (IPA) has successfully closed a public offering of 1,616,293 common shares at $13.45 per share, garnering approximately $21.7 million. H.C. Wainwright & Co. served as the sole book-running manager. Additionally, the underwriter has a 30-day option to purchase up to 242,443 additional shares. The funds will be utilized for expanding operations, developing internal therapeutic programs, enhancing technological capabilities, and advancing COVID-19 therapies.

ImmunoPrecise Antibodies Ltd. (IPA) has announced an increase in their public offering to 1,616,293 common shares at $13.45 each, yielding approximately $21.7 million in gross proceeds. The offering, managed by H.C. Wainwright & Co., is set to close around February 8, 2021. The funds will be utilized for expanding Good Laboratory Practice operations, developing Therapeutics through its subsidiary, and investing in cloud computing and sequencing technologies. An additional option for underwriters to buy 242,443 shares within 30 days has also been granted.

ImmunoPrecise Antibodies Ltd. (IPA) announced an underwriting agreement with H.C. Wainwright & Co. to sell 743,495 common shares at $13.45 each, generating approximately $10 million in gross proceeds. The offering closes around February 8, 2021. The underwriter can purchase an additional 111,524 shares within 30 days. Proceeds will fund expansion into Good Laboratory Practice and Good Manufacturing Practice-certified operations, Talem Therapeutics' program, and technology development. A base shelf prospectus was also filed with regulatory authorities for this offering.